New therapeutic strategies in systemic lupus erythematosus management
M Gatto, M Zen, L Iaccarino, A Doria - Nature Reviews Rheumatology, 2019 - nature.com
The current treatment approach for systemic lupus erythematosus (SLE), as outlined in the
recommendations by international medical associations including EULAR and the ACR, is …
recommendations by international medical associations including EULAR and the ACR, is …
Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren's syndrome: evidence-and practice-based guidance
A Marinho, J Delgado Alves, J Fortuna, R Faria… - Frontiers in …, 2023 - frontiersin.org
Systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and Sjögren's
syndrome (SS) are heterogeneous autoimmune diseases. Severe manifestations and …
syndrome (SS) are heterogeneous autoimmune diseases. Severe manifestations and …
The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus
T Kraaij, SWA Kamerling, ENM de Rooij… - Journal of …, 2018 - Elsevier
Objective In systemic lupus erythematosus (SLE) patients, excessive formation of neutrophil
extracellular traps (NETs) is observed and their degradation is impaired. In vitro, immune …
extracellular traps (NETs) is observed and their degradation is impaired. In vitro, immune …
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults …
Introduction Belimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the
treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a …
treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a …
Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody–associated vasculitis: a randomized controlled …
D Jayne, D Blockmans, R Luqmani… - Arthritis & …, 2019 - Wiley Online Library
Objective To evaluate the safety and efficacy of belimumab as adjunctive therapy to maintain
remission in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) …
remission in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) …
Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results
T Kraaij, EJ Arends, LS van Dam… - Nephrology Dialysis …, 2021 - academic.oup.com
Abstract Background Anti-CD20 B-cell depletion has not shown superior efficacy to standard
immunosuppression in patients with systemic lupus erythematosus (SLE). Besides trial …
immunosuppression in patients with systemic lupus erythematosus (SLE). Besides trial …
Current perspective on rituximab in rheumatic diseases
T Schioppo, F Ingegnoli - Drug design, development and therapy, 2017 - Taylor & Francis
The steadily increasing knowledge regarding pathogenetic mechanisms in autoimmune
rheumatic diseases has paved the way to different therapeutic approaches. In particular, the …
rheumatic diseases has paved the way to different therapeutic approaches. In particular, the …
Системная красная волчанка: новые горизонты диагностики и терапии
СК Соловьев, ЕА Асеева, ТВ Попкова… - Научно …, 2020 - cyberleninka.ru
Системная красная волчанка (СКВ)-системное аутоиммунное ревматическое
заболевание неизвестной этиологии, характеризующееся гиперпродукцией …
заболевание неизвестной этиологии, характеризующееся гиперпродукцией …
Low disease activity—irrespective of serologic status at baseline—associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus …
A Fanouriakis, C Adamichou, S Koutsoviti… - Seminars in arthritis and …, 2018 - Elsevier
Background Low disease activity is a validated target of current systemic lupus
erythematosus (SLE) therapy. The aim of this study was to assess the ability of belimumab to …
erythematosus (SLE) therapy. The aim of this study was to assess the ability of belimumab to …
Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: a systematic review
Abstract Both BLISS-52 and BLISS-76 international phase III trials in Systemic Lupus
Erythematosus (SLE) met their primary outcomes; however, they were not designed to …
Erythematosus (SLE) met their primary outcomes; however, they were not designed to …